Search Results
Mar 26, 2026, 09:00 ET SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
shares declined $2.40 per share, or 17.8%, in a single trading session on January 28, 2026, after the FDA placed a clinical hold on the Company's RGX-111 gene therapy program following discovery of a CNS tumor in a trial participant. The Court has set April 14, 2026 as the deadline to apply for lead plaintiff
More news about: SueWallSt.com
Mar 26, 2026, 08:11 ET Global Times: China hosts multiple key forums, spotlighting co-op, opening-up, to inject stability in an uncertain world
Innovation," this year's forum features more than 100 events, with in-depth discussions on areas such as 6G, brain computer interfaces, and cell and gene therapy.Immersed in this dynamic platform for technological innovation, several foreign guests told the Global Times reporters on Wednesday that
More news about: Global Times
Mar 26, 2026, 08:00 ET Averna Therapeutics Announces Strategic Leadership Expansion
Officer and Richard Morris appointed Chief Financial OfficerVeteran biopharma leaders to support advancement of the Company's gene insertion platform and strengthen operational excellence for long-term growthBOSTON, March
More news about: Averna Therapeutics
Mar 26, 2026, 03:21 ET Hansa Biopharma publishes 2025 Annual and Sustainability Reports
largest global transplant markets. In Europe, access to IDEFIRIX continued to grow, reflected by a 46% increase in product revenue. We also progressed our gene therapy programs, took a strategic decision to advance our next generation enzyme HNSA-5487 in autoimmune diseases, and continued to embed sustainability
More news about: Hansa Biopharma AB
Mar 26, 2026, 03:19 ET Hansa Biopharma publishes 2025 Annual and Sustainability Reports
largest global transplant markets. In Europe, access to IDEFIRIX continued to grow, reflected by a 46% increase in product revenue. We also progressed our gene therapy programs, took a strategic decision to advance our next generation enzyme HNSA-5487 in autoimmune diseases, and continued to embed sustainability
More news about: Hansa Biopharma AB
Mar 25, 2026, 15:19 ET Infosys to Acquire Leading Healthcare Digital Transformation Company, Optimum Healthcare IT
are pleased to welcome Optimum Healthcare and its leadership team to Infosys as we advance our shared vision for the future of healthcare."Gene Scheurer, Chief Executive Officer and Co-Founder of Optimum Healthcare IT, said, "From the beginning, Optimum was built to deliver results through
More news about: Infosys
Mar 25, 2026, 15:16 ET Infosys to Acquire Leading Healthcare Digital Transformation Company, Optimum Healthcare IT
are pleased to welcome Optimum Healthcare and its leadership team to Infosys as we advance our shared vision for the future of healthcare."Gene Scheurer, Chief Executive Officer and Co-Founder of Optimum Healthcare IT, said, "From the beginning, Optimum was built to deliver results through
More news about: Infosys
Mar 25, 2026, 14:55 ET Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Mar 25, 2026, 14:53 ET Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Mar 25, 2026, 13:46 ET Achieve Partners Signs Definitive Agreement to Sell Healthcare IT Services Leader to Infosys
systems across the country need new approaches that can both solve their near-term needs and lay the groundwork for a strong future talent pipeline," said Gene Scheurer, CEO of Optimum. "Optimum CareerPath has addressed both of those challenges. We're equally grateful to Achieve Partners for supporting the
More news about: Achieve Partners
Mar 25, 2026, 09:00 ET Merlin CP-GEP™ Demonstrates Superior Predictive Accuracy for Sentinel Lymph Node Metastasis in Early-Stage Melanoma
NCCN guideline thresholds. Merlin CP-GEP is a gene expression profile test recognized by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as predictive of SLN positivity risk, supported by validation in the largest, prospective, blinded, gene expression profile study in melanoma.
More news about: SkylineDx
Mar 25, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
Medical Officer, is named as an individual defendant in a securities class action alleging that his repeated public assurances about the safety of RGX-111 gene therapy concealed material risks from investors. When the truth emerged on January 28, 2026, RGNX shares fell $2.40 per share, a decline of 17.8%, closing
More news about: Levi & Korsinsky, LLP
Mar 25, 2026, 08:09 ET Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed
selectively disrupting the TBL1/β-catenin transcriptional complex, tegavivint promotes degradation of nuclear β-catenin and suppresses β-catenin-dependent gene transcription, inhibiting Wnt-driven tumor growth while avoiding the dose-limiting toxicities historically associated with upstream Wnt inhibition.Tegavivint
More news about: Iterion Therapeutics
Mar 25, 2026, 08:06 ET Jeremy Friedman, Owner of Rocky Mountain Liners, Honored by the Colorado Nursery and Greenhouse Association as Person of the Year 2025
Gene Pielin, president at
More news about: Rocky Mountain Liners
Mar 25, 2026, 08:00 ET Greenland Mines Secures Icebreaker Argus For 2026 Skaergaard Field Program
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80%
More news about: Greenland Mines Ltd
Mar 25, 2026, 06:05 ET MGI Tech Brings High-Throughput T7+ Sequencer to European Market at Analytica 2026 Debut
training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as one of the only providers
More news about: MGI Tech Co., Ltd.
Mar 25, 2026, 05:00 ET Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD
Complement Therapeutics to deepen our understanding of this promising one-time investigational gene therapy approach in patients with GA secondary to AMD." CTx001 is an investigational AAV2-based gene therapy designed to transduce retinal cells with a construct encoding mini-CR1, a truncated and
More news about: Complement
Mar 24, 2026, 19:17 ET uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed; April 13, 2026, Lead Plaintiff Deadline
COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During the Class Period, uniQure
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 24, 2026, 18:36 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Mar 24, 2026, 12:30 ET QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Mar 24, 2026, 11:39 ET International Harrington Prize Jointly Awarded to Drs. Arul Chinnaiyan and Charles Sawyers
together identified genetic changes that drive prostate cancer and pioneered breakthrough precision therapies. Dr. Chinnaiyan identified an abnormal gene fusion, TMPRSS2-ERG, that is the most common genetic driver of prostate cancer and is a foundational biomarker for prostate cancer diagnostics. Dr.
More news about: Harrington Discovery Institute
Mar 24, 2026, 11:05 ET Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
https://straitsresearch.com/report/cell-therapy-marketPrecedence Research, Cell and Gene Therapy Market Forecast — https://www.precedenceresearch.com/cell-and-gene-therapy-marketGrand View Research, CAR T-Cell Therapy Market
More news about: Equity Insider
Mar 24, 2026, 10:04 ET March of Dimes Awards Three Scientists Discovery Grants
Medicine. Dr. Lee is working to test whether suppressing a gene called HIF-2 could slow or eliminate preeclampsia once the disease has begun. If so, his work under the grant will also include identifying different drugs that can diminish the strength of the gene in hopes of identifying a possible treatment for
More news about: March of Dimes
Mar 24, 2026, 10:00 ET Advanced Cell-based Therapy Booming the Success for Healthcare Sector
https://straitsresearch.com/report/cell-therapy-market Precedence Research, Cell and Gene Therapy Market Forecast — https://www.precedenceresearch.com/cell-and-gene-therapy-market Grand View Research, CAR T-Cell Therapy
More news about: USA News Group
Mar 24, 2026, 09:00 ET RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: The Gross Law Firm